

UC Irvine

UC Irvine Previously Published Works

Title

Healthspan Pharmacology

Permalink

<https://escholarship.org/uc/item/2n36k9gf>

Journal

Rejuvenation Research, 18(6)

ISSN

1549-1684

Author

Jafari, Mahtab

Publication Date

2015-12-01

DOI

10.1089/rej.2015.1774

Peer reviewed

Healthspan Pharmacology

Mahtab Jafari

Abstract

The main goal of this paper is to present the case for shifting the focus of research on aging and anti-aging from lifespan pharmacology to what I like to call healthspan pharmacology, in which the desired outcome is the extension of healthy years of life rather than lifespan alone. Lifespan could be influenced by both genetic and epigenetic factors, but a long lifespan may not be a good indicator of an optimal healthspan. Without improving healthspan, prolonging longevity would have enormous negative socioeconomic outcomes for humans. Therefore, the goal of aging and anti-aging research should be to add healthy years to life and not merely to increase the chronological age. This article summarizes and compares two categories of pharmacologically induced lifespan extension studies in animal model systems from the last two decades—those reporting the effects of pharmacological interventions on lifespan extension alone versus others that include their effects on both lifespan and healthspan in the analysis. The conclusion is that the extrapolation of pharmacological results from animal studies to humans is likely to be more relevant when both lifespan and healthspan extension properties of pharmacological intervention are taken into account.

Introduction

AGING IS A COMPLEX AND MULTI-FACTORIAL process that is not well defined. The majority of evolutionary biologists, like Michael Rose, characterize aging as a decline or loss of adaptation with increasing age, caused by a time-progressive decline of William D. Hamilton's forces of natural selection.¹ Although there are a number of variants of this definition, we can all agree that as we age, we will experience a progressive accumulation of cellular damage and a degradation of repair and maintenance mechanisms, leading to a gradual deterioration of physiological functions. This process, which is highly conserved across species throughout evolution, creates progressive dysfunction associated with frailty and age-related diseases and eventually leads to the death of the organism.

Over recent decades, improvements in medical diagnostics and procedures, as well as improvements in hygiene, have resulted in a steady increase in human lifespan,^{2–10} but this increase has unfortunately been accompanied by ever-growing occurrences of diseases of aging, such as diabetes, neurodegenerative diseases, cancer, and cardiovascular diseases.¹¹ Therefore, understanding the mechanisms of aging, defining the most important risk factors for the development of chronic diseases of aging, and identifying pharmacological interventions to ameliorate the aging process are more important today than

ever. Over the last two decades, using several model systems, such as yeast, fruit flies, worms, and mice, numerous evolutionarily conserved pathways that regulate longevity have been identified, and the modification of these pathways either intrinsically (*e.g.*, genetic modifications for deletion, down-regulation or over-expression) or extrinsically (*e.g.*, environmental factors, use of pharmacological agents) have been shown to extend the lifespan of the model organisms.^{12–30}

Most of pharmacological intervention studies have focused on lifespan extension of animals, but very little attention has been given to the aspect of pharmacologically induced healthspan extension, which I refer to as healthspan pharmacology. Clearly, this omission is a serious one if results from animal studies are to be relevant to humans, many of whom consider their quality of life with advancing age to be just as important as their longevity. There appears to be an emergence of assays in animal models to evaluate healthspan. One of the tests that can be used to evaluate age-related changes in mice, in an effort to quantify the impact of pharmacological interventions on healthspan, is the frailty index (FI), also known as the index of cumulative deficits.^{31,32} A recent study with the goal of evaluating the utility of FI as a tool to evaluate the impact of caloric restriction and resveratrol on healthspan showed that these interventions reduced FI.³³ There is no obvious reason that this tool could not be used

TABLE 1. STUDIES FOCUSING ON LIFESPAN PHARMACOLOGY ONLY

<i>Intervention</i>	<i>Model organism</i>	<i>Mean lifespan extension</i>	<i>Mechanism of action</i>
α -ketoglutarate Chin et al., 2014 ⁴⁷	<i>C. elegans</i>	50%	Inhibition of ATP synthase and TOR signaling
<i>Alpinia zerumbet</i> Extract Upadhyay et al., 2013 ⁴⁸	<i>C. elegans</i>	23%	Anti-oxidant
Aspirin Strong et al., 2008 ⁴⁹	Mice	8% (male)	Anti-oxidant, anti-inflammatory
β -Guanidinopropionic acid Yang et al., 2015 ⁵⁰	<i>D. melanogaster</i>	Increase in mean lifespan	Activation of AMP-activated protein kinase, autophagy
Black tea Peng et al., 2009 ⁵¹	<i>D. melanogaster</i>	9.8%	Anti-oxidant
Blueberry extract Wilson et al., 2006 ⁵²	<i>C. elegans</i>	28%	Anti-oxidant
Blueberry extract Peng et al., 2012 ⁵³	<i>D. melanogaster</i>	10%	Anti-oxidant
Caffeic acid phenethyl ester Havermann et al., 2014 ⁵⁴	<i>C. elegans</i>	9–17%	Modulation of the insulin-like DAF-16 signaling
Chicoric acid Schlernitzauer et al., 2013 ⁵⁵	<i>C. elegans</i>	Increase in mean lifespan	Activation of AMP-kinase
Cinnamon Yu et al., 2010 ⁵⁶	<i>C. elegans</i>	12%	Regulation of Insulin/IGF-1 signaling
CoQ-10 Ishii et al., 2004 ⁵⁷	<i>C. elegans</i>	6–18%	Anti-oxidant
Diallyl trisulfide (garlic) Powolny et al., 2011 ⁵⁸	<i>C. elegans</i>	12–13%	Activation of SKN-1
Ethosuximide Collins et al., 2008 ⁵⁹	<i>C. elegans</i>	17%	Regulation of chemosensation
EUK-8/ EUK-134 Melov et al., 2000 ⁶⁰	<i>C. elegans</i>	44%	Anti-oxidant
Ginko biloba Wu et al., 2002 ⁶¹	<i>C. elegans</i>	8%	Anti-oxidant
Glucarubinone Zarse et al., 2011 ⁶²	<i>C. elegans</i>	Increase in mean lifespan	Induction of mitochondrial activity
Green tea Li et al., 2007 ⁶³	<i>D. melanogaster</i>	16–19%	Inhibition of iron accumulation, anti-oxidant
L-Theanine Zarse et al., 2012 ⁶⁴	<i>C. elegans</i>	Increase in mean lifespan	Anti-oxidant
Lipoic Acid Benedetti et al., 2008 ⁶⁵	<i>C. elegans</i>	21%	Anti-oxidant
Lithium McColl et al., 2008 ⁶⁶	<i>C. elegans</i>	46%	Modulation of histone methylation and chromatin structure
Lonidamine Schmeisser et al., 2011 ⁶⁷	<i>C. elegans</i>	8%	Anti-oxidant
Mainserin Petrascheck et al., 2007 ⁶⁸	<i>C. elegans</i>	31%	Activation of DR metabolism
Metformin Anisimov et al., 2008 ⁶⁹	Mice	38%	Activation of DR metabolism, oxidative stress
Metoprolol Spindler et al., 2013 ⁷⁰	Mice	10%	Inhibition of β -AR signaling
Myriocin Cutler et al., 2014 ⁷¹	<i>C. elegans</i>	24%	Decrease of ceramides
N-acetylcysteine Brack et al., 1997 ²⁵	<i>D. melanogaster</i>	27%	Differential gene expression
Natto extract Ibe et al., 2013 ⁷²	<i>C. elegans</i>	16%	Anti-oxidant
Oxaloacetic acid Williams et al., 2009 ⁷³	<i>C. elegans</i>	25%	Regulation of FOXO/DAF-16
Propyl gallate Benedetti et al., 2008 ⁶⁵	<i>C. elegans</i>	12%	Anti-oxidant

(continued)

TABLE 1. (CONTINUED)

<i>Intervention</i>	<i>Model organism</i>	<i>Mean lifespan extension</i>	<i>Mechanism of action</i>
Pyrrolidine dithiocarbamate (PDTC) Moskalev & Shaposhnikov 2011 ⁷⁴	<i>D. melanogaster</i>	20%	Inhibition of NF- κ B
Quercetin Kampkotter et al., 2008 ⁷⁵	<i>C. elegans</i>	15%	Anti-oxidant
Rapamycin Harrison et al., 2009 ²⁰	Mice	9–14%	Inhibition of the mTOR pathway
Resveratrol Howitz et al., 2003 ¹²	<i>S. cerevisiae</i>	70%	Activation of NAD ⁺ dependent protein deacetylases of the sirtuins
Resveratrol Viswanathan et al., 2005 ⁷⁶	<i>C. elegans</i>	10–14%	
<i>Rhodiola rosea</i> Bayliak & Lushchak 2011 ⁷⁷	<i>S. cerevisiae</i>	25%	Sensitization to oxidative stress
<i>Rhodiola rosea</i> Wiegant et al., 2009 ⁷⁸	<i>C. elegans</i>	10–20%	Increased stress resistance
Rifampicin Golegaonkar et al., 2015 ⁷⁹	<i>C. elegans</i>	60%	Activation of DAF-16
Spermidine Eisenberg et al., 2009 ⁸⁰	<i>C. elegans</i>	15%	Autophagy
Thioflavin T Alavez et al., 2011 ⁸¹ Tullet et al., 2008 ⁸²	<i>D. melanogaster</i> <i>C. elegans</i>	30% 60%	Inhibition of SKN-1
Tocotrienols Adachi et al., 2000 ⁸³	<i>C. elegans</i>	17%	Anti-oxidant
Trolox Benedetti et al., 2008 ⁶⁵	<i>C. elegans</i>	31%	Anti-oxidant
Vitamin E Harrington & Harley 1988 ⁸⁴	<i>C. elegans</i>	17–23%	Anti-oxidant

to quantify the effect of other pharmacological interventions on healthspan in animal model studies with the goal of extrapolating the results to humans.

The pharmacological agents that are known to extend lifespan in animal studies appear to act mainly through anti-oxidant defense, protein homeostasis, dietary restriction (DR) modulation, inhibition of kinases, or modulation of insulin/insulin-like growth factor (IGF) signaling. Among numerous agents that have been tested using multiple model systems over the last two decades, the spectrum includes anti-depressants (*e.g.*, mianserin), anti-convulsants (*e.g.*, valproic acid, lamotrigine), anti-diabetics (*e.g.*, metformin), immunosuppressants (*e.g.*, rapamycin), and natural products (*e.g.*, resveratrol, *Rhodiola rosea*, curcumin, green tea, blueberry). The mechanism of action and the extent of lifespan extension vary among each agent (Table 1), and most can be classified under the aforementioned groups. In addition to the widely known pharmacological interventions that prolong lifespan (*e.g.*, resveratrol, *Rhodiola rosea*, rapamycin, metformin) across species, high-throughput chemical screening approaches have been used to identify new candidate molecules that extend lifespan in *Caenorhabditis elegans* and *Drosophila melanogaster* model systems.^{14,34–40} With the convenience of *C. elegans* and *Drosophila* as platforms to discover new lifespan-extending compounds, it is inevitable that the number of identified anti-aging compounds that extend lifespan will continue to increase dramatically.

Although the end point of prolonged longevity is clear (*i.e.*, the death of the organism), the physiological mechanisms of extending lifespan via anti-aging interventions have been elusive. The implicit assumption that increasing the mean lifespan of a model organism not only delays aging but also the onset of the age-related physiological effects is unsupported and should be re-evaluated to include measurements of health parameters to determine if an intervention has the potential to add healthy years to the life of the model organism and eventually to humans. Even though a given intervention may extend the lifespan of the organism, if it decreases overall health, it should not be tested in a clinical study to evaluate its potential for human life prolongation, which is the ultimate goal of the longevity research.

The list of studies reporting lifespan extension via pharmacological agents (Table 1) is rather extensive compared to studies where healthspan was also taken into consideration (Table 2). There is no doubt that it is important to identify anti-aging compounds because, aside from their impact on lifespan, they will assist us in elucidating molecular pathways that may impact aging as outlined in Table 1. However, evaluating the impact of such compounds on healthspan is just as important as knowing their impact on lifespan.

The reason for this assertion is rather subtle. Although lifespan and healthspan have been thought to be highly correlated, recent reports indicate that they may not be as closely linked as previously thought. A recent study that uncoupled

TABLE 2. STUDIES FOCUSING ON BOTH LIFESPAN AND HEALTHSPAN PHARMACOLOGY

<i>Intervention</i>	<i>Model organism</i>	<i>Mean lifespan extension</i>	<i>Healthspan parameters</i>	<i>Mechanism of action</i>
4-phenylbutyrate (PBA) Kang et al., 2002 ⁸⁵	<i>D. melanogaster</i>	33%	Locomotion, reproduction	Increased histone acetylation
Caffeine Sutphin et al., 2012 ⁸⁶	<i>C. elegans</i>	37%	Locomotion	Regulation of Insulin/IGF-1 signaling
Catechin Saul et al., 2009 ⁸⁷	<i>C. elegans</i>	12–14%	Reproduction, pharyngeal pumping	Stress resistance
Celecoxib Ching et al., 2011 ⁸⁸	<i>C. elegans</i>	20%	Locomotion	Inhibition of PDK-1
Cinnamon Schriner et al., 2014 ⁸⁹	<i>D. melanogaster</i>	12–24%	Reproduction, locomotion	Regulation of Insulin/IGF-1 signaling
Curcumin Alavez et al., 2011 ⁸¹	<i>C. elegans</i>	45%	Locomotion	Activation of HSF-1 and SKN-1
Curcumin Lee et al., 2010 ⁹⁰	<i>D. melanogaster</i>	16–19%	Reproduction, locomotion	
Dichloroacetate Schaffer et al., 2011 ⁹¹	<i>C. elegans</i>	Increase in mean lifespan	Locomotion	Inhibition of pyruvate dehydrogenase kinase
Ethosuximide Evason et al., 2005 ⁹²	<i>C. elegans</i>	17%	Reproduction, locomotion, pharyngeal pumping	Regulation of chemosensation
Green tea Lopez et al., 2014 ⁹³	<i>D. melanogaster</i>	16–19%	Reproduction	Inhibition of iron accumulation, anti-oxidant
Icariin & Icariside II Cai et al., 2011 ⁹⁴	<i>C. elegans</i>	21%	Locomotion	Regulation of Insulin/IGF-1 signaling
Lamotrigine Avanesian et al., 2010 ⁴⁵	<i>D. melanogaster</i>	12–17%	Locomotion	Metabolic rate depression
Metformin Onken & Driscoll, 2010 ⁴⁴	<i>C. elegans</i>	40%	Locomotion	Activation of DR metabolism, oxidative stress
Metformin Anisimov et al., 2008 ⁶⁹	Mice	38%	Estrus, metabolic parameters	
Metoprolol Spindler et al., 2013 ⁷⁰	<i>D. melanogaster</i>	23%	Locomotion	Inhibition of β -AR signaling
Nordihydroguaiaretic acid (NDGA) Harrison et al., 2014 ⁹⁵	Mice	12%	Metabolic markers	Anti-oxidant, anti-inflammatory
Quercetin Pietsch et al., 2009 ⁹⁶	<i>C. elegans</i>	15%	Reproduction	Anti-oxidant
Rapamycin Bjedov et al., 2010 ⁹⁷	<i>D. melanogaster</i>	Increase in mean lifespan	Reproduction	Inhibition of the TOR pathway
Rapamycin Zhang et al., 2013 ⁹⁸	Mice	Decrease in mortality	Locomotion, reduced sleep fragmentation	Inhibition of the mTOR pathway
<i>Rhodiola rosea</i> Schriner et al., 2009 ⁹⁹ 2013 ²⁸	<i>D. melanogaster</i>	24%	Reproduction, locomotion	Decrease in endogenous superoxide levels, DR-Independent lifespan extension

(continued)

TABLE 2. (CONTINUED)

<i>Intervention</i>	<i>Model organism</i>	<i>Mean lifespan extension</i>	<i>Healthspan parameters</i>	<i>Mechanism of action</i>
<i>Rosa damascena</i> Jafari et al., 2008 ¹⁰⁰ Schriner et al., 2012 ¹⁰¹	<i>D. melanogaster</i>	16% (males)	Reproduction	Heat shock proteins
Reserpine Srivastava et al., 2008 ¹⁰²	<i>C. elegans</i>	31–64%	Locomotion, pharyngeal pumping	Increased stress tolerance
Resveratrol Wood et al., 2004 ¹⁰³	<i>C. elegans</i>	10–14%	Reproduction, pharyngeal pumping	Activation of NAD+ dependent protein deacetylases of the sirtuins
Resveratrol Baur et al., 2006 ¹⁰⁴	<i>D. melanogaster</i> Mice	29% 31% reduction in the risk of death from a high-calorie diet	Reproduction Organ pathology	
Trehalose Honda et al., 2010 ¹⁰⁵	<i>C. elegans</i>	30%	Reproduction, pharyngeal pumping	Reduced Insulin/IGF-1 signaling
Trimethadione Evason et al., 2005 ⁹²	<i>C. elegans</i>	47%	Reproduction, locomotion, pharyngeal pumping	Regulation of neural activity
Valproic acid Evason et al., 2008 ¹⁰⁶	<i>C. elegans</i>	35%	Reproduction, locomotion	Regulation of Insulin/ IGF-1 signaling

lifespan and healthspan in *C. elegans* by examining wild-type and four long-lived mutants provided evidence that in a number of cases, where lifespan was extended, the health of the worms suffered drastically.⁴¹ Given that life expectancy has been on the rise for humans, further extending lifespan alone without improving healthspan will have significant adverse outcomes, such as unmanageable health care costs due to declined quality of life and increased incidence of age-related diseases, which further underscores the importance of studying healthspan as opposed to just lifespan.

Healthspan Pharmacology

Despite the necessity of evaluating healthspan in the context of lifespan, a comprehensive definition of healthspan in the laboratory requires an all-inclusive approach defining and evaluating a number of physiological parameters that contribute to the state of health. Describing measurable parameters to determine healthspan is more challenging compared to lifespan, which is simply measured by the mean and maximum life expectancy of the organism. A few parameters for healthspan have been utilized for invertebrates model systems. For instance, movement and feeding behaviors have been used as healthspan markers for *C. elegans*,^{41–44} whereas locomotion and reproduction serve as the indicators of health for *D. melanogaster*.⁴⁵ Not surprisingly, when it comes to a mammalian model system, such as mice, the definition of healthspan parameters becomes more complex. Even though there are a number of validated tests that measure behavior, locomotion, cognition, and metabolism in young mice, there is no uniform set of tests to measure healthspan in aging mice. A recent perspective article⁴⁶ put forward several recommendations

for measuring healthspan in mice in an effort to provide a unified method of focusing on healthspan in aging research. Perhaps the FI that measures cumulative deficits in mice can also be incorporated to quantify the impact of pharmacological interventions on healthspan. Given the challenge of reproducibility of a specified connection between a compound and lifespan extension among different laboratories around the world, correlating the effects of pharmacological interventions with healthspan will be even more challenging.

In conclusion, to extrapolate the result of any potential anti-aging pharmacological agent from the laboratory model systems to humans, evaluation of healthspan absolutely needs to be part of the equation. This is why we now need to shift the focus of the scientific community studying aging and anti-aging from lifespan pharmacology to healthspan pharmacology.

Author Disclosure Statement

No competing financial interests exist.

References

1. Rose MR. *Evolutionary Biology of Aging*. Oxford University Press, New York, 1991.
2. Jeune B. Living longer—but better? *Aging Clin Exp Res* 2002;14:72–93.
3. Olshansky SJ, Carnes BA, Cassel C. In search of Methuselah: Estimating the upper limits to human longevity. *Science* 1990;250:634–640.
4. Vaupel JW, Gowan AE. Passage to Methuselah: Some demographic consequences of continued progress against mortality. *Am J Public Health* 1986;76:430–433.

5. Manton KG, Stallard E. Cross-sectional estimates of active life expectancy for the U.S. elderly and oldest-old populations. *J Gerontol* 1991;46:S170–S182.
6. Vaupel JW. The remarkable improvements in survival at older ages. *Philos Trans R Soc Lond B Biol Sci* 1997;352:1799–1804.
7. Tuljapurkar S, Li N, Boe C. A universal pattern of mortality decline in the G7 countries. *Nature* 2000;405:789–792.
8. Oeppen J, Vaupel JW. Demography. Broken limits to life expectancy. *Science* 2002;296:1029–1031.
9. Cheung SL, Robine JM. Increase in common longevity and the compression of mortality: The case of Japan. *Popul Stud (Camb)* 2007;61:85–97.
10. Christensen K, Doblhammer G, Rau R, Vaupel JW. Ageing populations: The challenges ahead. *Lancet* 2009;374:1196–1208.
11. De Grey ADNJ, Rae M. *Ending Aging: The Rejuvenation Breakthroughs That Could Reverse Human Aging in Our Lifetime*, 1st ed. St. Martin's Press, New York, 2007.
12. Howitz KT, Bitterman KJ, Cohen HY, Lamming DW, Lavu S, Wood JG, Zipkin RE, Chung P, Kisielewski A, Zhang LL, Scherer B, Sinclair DA. Small molecule activators of sirtuins extend *Saccharomyces cerevisiae* lifespan. *Nature* 2003;425:191–196.
13. Gruber J, Ng LF, Poovathingal SK, Halliwell B. Deceptively simple but simply deceptive—*Caenorhabditis elegans* lifespan studies: Considerations for aging and antioxidant effects. *FEBS Lett* 2009;583:3377–3387.
14. Petrascheck M, Ye X, Buck LB. A high-throughput screen for chemicals that increase the lifespan of *Caenorhabditis elegans*. *Ann NY Acad Sci* 2009;1170:698–701.
15. Chen M, Huang L, Shabier Z, Wang J. Regulation of the lifespan in dendritic cell subsets. *Mol Immunol* 2007;44:2558–2565.
16. Jafari M. *Drosophila melanogaster* as a model system for the evaluation of anti-aging compounds. *Fly (Austin)* 2010;4:253–257.
17. Donmez G, Guarente L. Aging and disease: Connections to sirtuins. *Aging Cell* 2010;9:285–290.
18. Kenyon CJ. The genetics of ageing. *Nature* 2010;464:504–512.
19. Holzenberger M, Dupont J, Ducos B, Leneuve P, Géloën A, Even PC, Cervera P, Le Bouc Y. IGF-1 receptor regulates lifespan and resistance to oxidative stress in mice. *Nature* 2003;421:182–187.
20. Harrison DE, Strong R, Sharp ZD, Nelson JF, Astle CM, Flurkey K, Nadon NL, Wilkinson JE, Frenkel K, Carter CS, Pahor M, Javors MA, Fernandez E, Miller RA. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. *Nature* 2009;460:392–395.
21. Lamming DW, Ye L, Katajisto P, Goncalves MD, Saitoh M, Stevens DM, Davis JG, Salmon AB, Richardson A, Ahima RS, Guertin DA, Sabatini DM, Baur JA. Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity. *Science* 2012;335:1638–1643.
22. Robida-Stubbs S, Glover-Cutter K, Lamming DW, Mizunuma M, Narasimhan SD, Neumann-Haefelin E, Sabatini DM, Blackwell TK. TOR signaling and rapamycin influence longevity by regulating SKN-1/Nrf and DAF-16/FoxO. *Cell Metab* 2012;15:713–724.
23. Johnson TE. Increased life-span of age-1 mutants in *Caenorhabditis elegans* and lower Gompertz rate of aging. *Science* 1990;249:908–912.
24. Lee GD, Wilson MA, Zhu M, Wolkow CA, de Cabo R, Ingram DK, Zou S. Dietary deprivation extends lifespan in *Caenorhabditis elegans*. *Aging Cell* 2006;5:515–524.
25. Brack C, Bechter-Thuring E, Labuhn M. N-acetylcysteine slows down ageing and increases the life span of *Drosophila melanogaster*. *Cell Mol Life Sci* 1997;53:960–966.
26. Friedman DB, Johnson TE. A mutation in the age-1 gene in *Caenorhabditis elegans* lengthens life and reduces hermaphrodite fertility. *Genetics* 1988;118:75–86.
27. Jafari M, Felgner JS, Bussel, II, et al. *Rhodiola*: A promising anti-aging Chinese herb. *Rejuvenation Res*. Dec 2007;10(4):587–602.
28. Schriener SE, Lee K, Truong S, Hutchili T, Khodayari B, Rose MR, Vince-Cruz C, Mueller LD. Extension of *Drosophila* lifespan by *Rhodiola rosea* through a mechanism independent from dietary restriction. *PLoS One* 2013;8:e63886.
29. Clancy DJ, Gems D, Harshman LG, Oldham S, Stocker H, Hafen E, Leevers SJ, Partridge L. Extension of life-span by loss of CHICO, a *Drosophila* insulin receptor substrate protein. *Science* 2001;292:104–106.
30. Parkes TL, Elia AJ, Dickinson D, Hilliker AJ, Phillips JP, Boulianne GL. Extension of *Drosophila* lifespan by overexpression of human SOD1 in motorneurons. *Nat Genet* 1998;19:171–174.
31. Parks RJ, Fares E, Macdonald JK, Ernst MC, Sinal CJ, Rockwood K, Howlett SE. A procedure for creating a frailty index based on deficit accumulation in aging mice. *J Gerontol A Biol Sci Med Sci* 2012;67:217–227.
32. Whitehead JC, Hildebrand BA, Sun M, Rockwood MR, Rose RA, Rockwood K, Howlett SE. A clinical frailty index in aging mice: Comparisons with frailty index data in humans. *J Gerontol A Biol Sci Med Sci* 2014;69:621–632.
33. Kane AE, Hilmer SN, Boyer D, Gavin K, Nines D, Howlett SE, de Cabo R, Mitchell SJ. Impact of longevity interventions on a validated mouse clinical frailty index. *J Gerontol A Biol Sci Med Sci*. 2015; Feb 22 pii: glu315.
34. Ye X, Linton JM, Schork NJ, Buck LB, Petrascheck M. A pharmacological network for lifespan extension in *Caenorhabditis elegans*. *Aging Cell* 2014;13:206–215.
35. Burns AR, Kwok TC, Howard A, Houston E, Johanson K, Chan A, Cutler SR, McCourt P, Roy PJ. High-throughput screening of small molecules for bioactivity and target identification in *Caenorhabditis elegans*. *Nat Protoc* 2006;1:1906–1914.
36. Kwok TC, Ricker N, Fraser R, Chan AW, Burns A, Stanley EF, McCourt P, Cutler SR, Roy PJ. A small-molecule screen in *C. elegans* yields a new calcium channel antagonist. *Nature* 2006;441:91–95.
37. Qurashi A, Liu H, Ray L, Nelson DL, Duan R, Jin P. Chemical screen reveals small molecules suppressing fragile X pre-mutation rCGG repeat-mediated neurodegeneration in *Drosophila*. *Hum Mol Genet* 2012;21:2068–2075.
38. Gasque G, Conway S, Huang J, Rao Y, Vosshall LB. Small molecule drug screening in *Drosophila* identifies the 5HT2A receptor as a feeding modulation target. *Sci Rep* 2013;3:srep02120.
39. Perrimon N, Friedman A, Mathey-Prevot B, Eggert US. Drug-target identification in *Drosophila* cells: Combining high-throughput RNAi and small-molecule screens. *Drug Discov Today* 2007;12:28–33.

40. Spindler SR, Li R, Dhabhi JM, Yamakawa A, Sauer F. Novel protein kinase signaling systems regulating lifespan identified by small molecule library screening using *Drosophila*. *PLoS One* 2012;7:e29782.
41. Bansal A, Zhu LJ, Yen K, Tissenbaum HA. Uncoupling lifespan and healthspan in *Caenorhabditis elegans* longevity mutants. *Proc Natl Acad Sci USA* 2015;112:E277–E286.
42. Gerstbrein B, Stamatias G, Kollias N, Driscoll M. In vivo spectrofluorimetry reveals endogenous biomarkers that report healthspan and dietary restriction in *Caenorhabditis elegans*. *Aging Cell* 2005;4:127–137.
43. Iwasa H, Yu S, Xue J, Driscoll M. Novel EGF pathway regulators modulate *C. elegans* healthspan and lifespan via EGF receptor, PLC-gamma, and IP3R activation. *Aging Cell* 2010;9:490–505.
44. Onken B, Driscoll M. Metformin induces a dietary restriction-like state and the oxidative stress response to extend *C. elegans* healthspan via AMPK, LKB1, and SKN-1. *PLoS One* 2010;5:e8758.
45. Avanesian A, Khodayari B, Felgner JS, Jafari M. Lamotrigine extends lifespan but compromises health span in *Drosophila melanogaster*. *Biogerontology* 2010;11:45–52.
46. Richardson A, Fischer KE, Speakman JR, de Cabo R, Mitchell SJ, Peterson CA, Rabinovitch P, Chiao YA, Taffet G, Miller RA, Rentería RC, Bower J, Ingram DK, Ladiges WC, Ikeno Y, Sierra F, Austad SN. Measures of healthspan as indices of aging in mice—a recommendation. *J Gerontol A Biol Sci Med Sci*. 2015; Aug 22 pii: glv080.
47. Chin RM, Fu X, Pai MY, et al. The metabolite alpha-ketoglutarate extends lifespan by inhibiting ATP synthase and TOR. *Nature* 2014;510:397–401.
48. Upadhyay A, Chompoo J, Taira N, et al. Significant longevity-extending effects of *Alpinia zerumbet* leaf extract on the life span of *Caenorhabditis elegans*. *Biosci Biotechnol Biochem*. 2013;77:217–223.
49. Strong R, Miller RA, Astle CM, et al. Nordihydroguaiaretic acid and aspirin increase lifespan of genetically heterogeneous male mice. *Aging Cell* 2008;7:641–650.
50. Yang S, Long LH, Li D, et al. beta-Guanidinopropionic acid extends the lifespan of *Drosophila melanogaster* via an AMP-activated protein kinase-dependent increase in autophagy. *Aging Cell* 2015; Epub ahead of print. DOI: 10.1111/ace1.12371.
51. Peng C, Chan HY, Li YM, et al. Black tea theaflavins extend the lifespan of fruit flies. *Exp Gerontol*. Dec 2009;44:773–783.
52. Wilson MA, Shukitt-Hale B, Kalt W, et al. Blueberry polyphenols increase lifespan and thermotolerance in *Caenorhabditis elegans*. *Aging Cell* Feb 2006;5:59–68.
53. Peng C, Zuo Y, Kwan KM, et al. Blueberry extract prolongs lifespan of *Drosophila melanogaster*. *Exp Gerontol* Feb 2012;47:170–178.
54. Havermann S, Chovolou Y, Humpf HU, Watjen W. Caffeic acid phenylester increases stress resistance and enhances lifespan in *Caenorhabditis elegans* by modulation of the insulin-like DAF-16 signalling pathway. *PLoS One* 2014;9:e100256.
55. Schlernitzauer A, Oiry C, Hamad R, et al. Chicoric acid is an antioxidant molecule that stimulates AMP kinase pathway in L6 myotubes and extends lifespan in *Caenorhabditis elegans*. *PLoS One* 2013;8:e78788.
56. Yu YB, Dosanjh L, Lao L, et al. Cinnamomum cassia bark in two herbal formulas increases life span in *Caenorhabditis elegans* via insulin signaling and stress response pathways. *PLoS One* 2010;5:e9339.
57. Ishii N, Senoo-Matsuda N, Miyake K, et al. Coenzyme Q10 can prolong *C. elegans* lifespan by lowering oxidative stress. *Mech Ageing Dev* 2004;125:41–46.
58. Powolny AA, Singh SV, Melov S, et al. The garlic constituent diallyl trisulfide increases the lifespan of *C. elegans* via *skn-1* activation. *Exp Gerontol* 2011;46:441–452.
59. Collins JJ, Evason K, Pickett CL, et al. The anticonvulsant ethosuximide disrupts sensory function to extend *C. elegans* lifespan. *PLoS Genet* 2008;4:e1000230.
60. Melov S, Ravenscroft J, Malik S, et al. Extension of lifespan with superoxide dismutase/catalase mimetics. *Science* 2000;289:1567–1569.
61. Wu Z, Smith JV, Paramasivam V, et al. Ginkgo biloba extract EGb 761 increases stress resistance and extends life span of *Caenorhabditis elegans*. *Cell Mol Biol (Noisy-le-grand)*. 2002;48:725–731.
62. Zarse K, Bossecker A, Muller-Kuhrt L, et al. The phytochemical glaucarubinone promotes mitochondrial metabolism, reduces body fat, and extends lifespan of *Caenorhabditis elegans*. *Horm Metab Res* 2011;43:241–243.
63. Li YM, Chan HY, Huang Y, Chen ZY. Green tea catechins upregulate superoxide dismutase and catalase in fruit flies. *Mol Nutr Food Res* 2007;51:546–554.
64. Zarse K, Jabin S, Ristow M. L-Theanine extends lifespan of adult *Caenorhabditis elegans*. *Eur J Nutr* 2012;51:765–768.
65. Benedetti MG, Foster AL, Vantipalli MC, et al. Compounds that confer thermal stress resistance and extended lifespan. *Exp Gerontol* 2008;43:882–891.
66. McColl G, Killilea DW, Hubbard AE, et al. Pharmacogenetic analysis of lithium-induced delayed aging in *Caenorhabditis elegans*. *J Biol Chem* 2008;283:350–357.
67. Schmeisser S, Zarse K, Ristow M. Lonidamine extends lifespan of adult *Caenorhabditis elegans* by increasing the formation of mitochondrial reactive oxygen species. *Horm Metab Res* 2011;43:687–692.
68. Petrascheck M, Ye X, Buck LB. An antidepressant that extends lifespan in adult *Caenorhabditis elegans*. *Nature* 2007;450:553–556.
69. Anisimov VN, Berstein LM, Egorin PA, et al. Metformin slows down aging and extends life span of female SHR mice. *Cell Cycle* 2008;7:2769–2773.
70. Spindler SR, Mote PL, Li R, et al. beta1-Adrenergic receptor blockade extends the life span of *Drosophila* and long-lived mice. *Age (Dordr)* 2013;35:2099–2109.
71. Cutler RG, Thompson KW, Camandola S, et al. Sphingolipid metabolism regulates development and lifespan in *Caenorhabditis elegans*. *Mech Ageing Dev* 2014;143:144:9–18.
72. Ibe S, Kumada K, Yoshida K, Otake K. Natto (fermented soybean) extract extends the adult lifespan of *Caenorhabditis elegans*. *Biosci Biotechnol Biochem* 2013;77:392–394.
73. Williams DS, Cash A, Hamadani L, Diemer T. Oxaloacetate supplementation increases lifespan in *Caenorhabditis elegans* through an AMPK/FOXO-dependent pathway. *Aging Cell* 2009;8:765–768.
74. Moskalev A, Shaposhnikov M. Pharmacological inhibition of NF-kappaB prolongs lifespan of *Drosophila melanogaster*. *Aging* 2011;3:391–394.

75. Kampkotter A, Timpel C, Zurawski RF, et al. Increase of stress resistance and lifespan of *Caenorhabditis elegans* by quercetin. *Comp Biochem Physiol B Biochem Mol Biol* 2008;149:314–323.
76. Viswanathan M, Kim SK, Berdichevsky A, Guarente L. A role for SIR-2.1 regulation of ER stress response genes in determining *C. elegans* life span. *Dev Cell* 2005;9:605–615.
77. Bayliak MM, Lushchak VI. The golden root, *Rhodiola rosea*, prolongs lifespan but decreases oxidative stress resistance in yeast *Saccharomyces cerevisiae*. *Phytomedicine* 2011;18:1262–1268.
78. Wiegant FA, Surinova S, Ytsma E, et al. Plant adaptogens increase lifespan and stress resistance in *C. elegans*. *Biogerontology* 2009;10:27–42.
79. Golegaonkar S, Tabrez SS, Pandit A, et al. Rifampicin reduces advanced glycation end products and activates DAF-16 to increase lifespan in *Caenorhabditis elegans*. *Aging Cell* 2015;14:463–473.
80. Eisenberg T, Knauer H, Schauer A, et al. Induction of autophagy by spermidine promotes longevity. *Nat Cell Biol* 2009;11:1305–1314.
81. Alavez S, Vantipalli MC, Zucker DJ, et al. Amyloid-binding compounds maintain protein homeostasis during ageing and extend lifespan. *Nature* 2011;472:226–229.
82. Tullet JM, Hertweck M, An JH, et al. Direct inhibition of the longevity-promoting factor SKN-1 by insulin-like signaling in *C. elegans*. *Cell* 2008;132:1025–1038.
83. Adachi H, Ishii N. Effects of tocotrienols on life span and protein carbonylation in *Caenorhabditis elegans*. *J Gerontol A Biol Sci Med Sci* 2000;55:B280–285.
84. Harrington LA, Harley CB. Effect of vitamin E on lifespan and reproduction in *Caenorhabditis elegans*. *Mech Ageing Dev* 1988;43:71–78.
85. Kang HL, Benzer S, Min KT. Life extension in *Drosophila* by feeding a drug. *Proc Natl Acad Sci U S A* 2002;99:838–843.
86. Sutphin GL, Bishop E, Yanos ME, et al. Caffeine extends life span, improves healthspan, and delays age-associated pathology in *Caenorhabditis elegans*. *Longev Healthspan* 2012;1:9.
87. Saul N, Pietsch K, Menzel R, et al. Catechin induced longevity in *C. elegans*: from key regulator genes to disposable soma. *Mech Ageing Dev* 2009;130:477–486.
88. Ching TT, Chiang WC, Chen CS, Hsu AL. Celecoxib extends *C. elegans* lifespan via inhibition of insulin-like signaling but not cyclooxygenase-2 activity. *Aging Cell* 2011;10:506–519.
89. Schriener SE, Kuramada S, Lopez TE, et al. Extension of *Drosophila* lifespan by cinnamon through a sex-specific dependence on the insulin receptor substrate chico. *Exp Gerontol* 2014;60:220–230.
90. Lee KS, Lee BS, Semnani S, et al. Curcumin extends life span, improves health span, and modulates the expression of age-associated aging genes in *Drosophila melanogaster*. *Rejuvenation Res* 2010;13:561–570.
91. Schaffer S, Gruber J, Ng LF, et al. The effect of dichloroacetate on health- and lifespan in *C. elegans*. *Biogerontology* 2011;12:195–209.
92. Evason K, Huang C, Yamben I, et al. Anticonvulsant medications extend worm life-span. *Science* 2005;307:258–262.
93. Lopez T, Schriener SE, Okoro M, et al. Green tea polyphenols extend the lifespan of male *Drosophila melanogaster* while impairing reproductive fitness. *J Med Food* 2014;17:1314–1321.
94. Cai WJ, Huang JH, Zhang SQ, et al. Icaritin and its derivative icariside II extend healthspan via insulin/IGF-1 pathway in *C. elegans*. *PLoS One* 2011;6:e28835.
95. Harrison DE, Strong R, Allison DB, et al. Acarbose, 17-alpha-estradiol, and nordihydroguaiaretic acid extend mouse lifespan preferentially in males. *Aging Cell* 2014;13:273–282.
96. Pietsch K, Saul N, Menzel R, et al. Quercetin mediated lifespan extension in *Caenorhabditis elegans* is modulated by age-1, daf-2, sek-1 and unc-43. *Biogerontology* 2009;10(5):565–578.
97. Bjedov I, Toivonen JM, Kerr F, et al. Mechanisms of life span extension by rapamycin in the fruit fly *Drosophila melanogaster*. *Cell Metab* 2010;11:35–46.
98. Zhang Y, Bokov A, Gelfond J, et al. Rapamycin extends life and health in C57BL/6 mice. *J Gerontol A Biol Sci Med Sci* 2014;69:119–130.
99. Schriener SE, Abrahamyan A, Avanesian A, et al. Decreased mitochondrial superoxide levels and enhanced protection against paraquat in *Drosophila melanogaster* supplemented with *Rhodiola rosea*. *Free Radic Res* 2009;43:836–843.
100. Jafari M, Zarban A, Pham S, Wang T. *Rosa damascena* decreased mortality in adult *Drosophila*. *J Med Food* 2008;11:9–13.
101. Schriener SE, Katozi NS, Pham KQ, et al. Extension of *Drosophila* lifespan by *Rosa damascena* associated with an increased sensitivity to heat. *Biogerontology* 2012;13:105–117.
102. Srivastava D, Arya U, SoundaraRajan T, et al. Reserpine can confer stress tolerance and lifespan extension in the nematode *C. elegans*. *Biogerontology* 2008;9:309–316.
103. Wood JG, Rogina B, Lavu S, et al. Sirtuin activators mimic caloric restriction and delay ageing in metazoans. *Nature* 2004;430:686–689.
104. Baur JA, Pearson KJ, Price NL, et al. Resveratrol improves health and survival of mice on a high-calorie diet. *Nature* 2006;444:337–342.
105. Honda Y, Tanaka M, Honda S. Trehalose extends longevity in the nematode *Caenorhabditis elegans*. *Aging Cell* 2010;9:558–569.
106. Evason K, Collins JJ, Huang C, et al. Valproic acid extends *Caenorhabditis elegans* lifespan. *Aging Cell* 2008;7:305–317.

Address correspondence to:

Mahtab Jafari
 Department of Pharmaceutical Sciences
 University of California Irvine
 3232 McGaugh Hall
 Irvine, CA 92697

E-mail: mjafari@uci.edu

Received: September 14, 2015

Accepted: October 7, 2015